Multiparametric functional MRI and $^{18}$F-FDG-PET for survival prediction in patients with head and neck squamous cell carcinoma treated with (chemo)radiation

Roland M. Martens$^1$ · Thomas Koopman$^1$ · Cristina Lavini$^2$ · Meedie Ali$^1$ · Carel F. W. Peeters$^3$ · Daniel P. Noij$^1$ · Gerben Zwezerijnen$^1$ · J. Tim Marcus$^1$ · Marije R. Vergeer$^4$ · C. René Leemans$^5$ · Remco de Bree$^6$ · Pim de Graaf$^1$ · Ronald Boellaard$^1$ · Jonas A. Castelijns$^1$

Received: 21 May 2020 / Revised: 17 June 2020 / Accepted: 6 August 2020 / Published online: 26 August 2020 © The Author(s) 2020

Abstract

Objectives To assess (I) correlations between diffusion-weighted (DWI), intravoxel incoherent motion (IVIM), dynamic contrast-enhanced (DCE) MRI, and $^{18}$F-FDG-PET/CT imaging parameters capturing tumor characteristics and (II) their predictive value of locoregional recurrence-free survival (LRFS) and overall survival (OS) in patients with head and neck squamous cell carcinoma (HNSCC) treated with (chemo)radiotherapy.

Methods Between 2014 and 2018, patients with histopathologically proven HNSCC, planned for curative (chemo) radiotherapy, were prospectively included. Pretreatment clinical, anatomical, and functional imaging parameters (obtained by DWI/IVIM, DCE-MRI, and $^{18}$F-FDG-PET/CT) were extracted for primary tumors (PT) and lymph node metastases. Correlations and differences between parameters were assessed. The predictive value of LRFS and OS was assessed, performing univariable, multivariable Cox and CoxBoost regression analyses.

Results In total, 70 patients were included. Significant correlations between $^{18}$F-FDG-PET parameters and DWI-/DCE volume parameters were found ($r > 0.442$, $p < 0.002$). The combination of HPV (HR = 0.903), intoxications (HR = 1.065), PT ADC$_{GTV}$ (HR = 1.252), $K^{\text{trans}}$ (HR = 1.223), and $V_e$ (HR = 1.215) was predictive for LRFS (C-index = 0.546; $p = 0.023$). N-stage (HR = 1.058), HPV positivity (HR = 0.886), hypopharyngeal tumor location (HR = 1.111), ADC$_{GTV}$ (HR = 1.102), ADC$_{mean}$ (HR = 1.137), $D^*$ (HR = 0.862), $K^{\text{trans}}$ (HR = 1.106), $V_e$ (HR = 1.195), SUV$_{\text{max}}$ (HR = 1.094), and TLG (HR = 1.433) were predictive for OS (C-index = 0.664; $p = 0.046$).

Conclusions Functional imaging parameters, performing DWI/IVIM, DCE-MRI, and $^{18}$F-FDG-PET/CT, yielded complementary value in capturing tumor characteristics. More specific, intoxications, HPV-negative status, large tumor volume-related parameters, high permeability ($K^{\text{trans}}$), and high extravascular extracellular space ($V_e$) parameters were predictive for adverse
locoregional recurrence-free survival and adverse overall survival. Low cellularity (high ADC) and high metabolism (high SUV) were additionally predictive for decreased overall survival. These different predictive factors added to estimated locoregional and overall survival.

**Key Points**
- Parameters of DWI/IVIM, DCE-MRI, and 18F-FDG-PET/CT were able to capture complementary tumor characteristics.
- Multivariable analysis revealed that intoxications, HPV negativity, large tumor volume and high vascular permeability ($K_{\text{trans}}$), and extravascular extravascular space ($V_e$) were complementary predictive for locoregional recurrence.
- In addition to predictive parameters for locoregional recurrence, also high cellularity (low ADC) and high metabolism (high SUV) were complementary predictive for overall survival.

**Keywords** Squamous cell carcinoma of head and neck · Diffusion magnetic resonance imaging · Magnetic resonance imaging · Positron emission tomography computed tomography · Survival analysis

**Abbreviations**
- AIF: Arterial input function
- AJCC: American Joint Committee on Cancer
- D: Pure diffusion coefficient
- D*: Pseudo-diffusion coefficient
- f: Perfusion fraction
- GTV: Gross tumor volume
- IVIM: Intravoxel incoherent motion
- $K_{\text{ep}}$: The rate constant for transfer of contrast agent from extravascular, extracellular space to the plasma
- $K_{\text{trans}}$: The rate constant for transfer of contrast agent from plasma to extravascular, extracellular space
- $V_e$: The fractional volume of extravascular extracellular space

**Introduction**

In patients with advanced stage head and neck squamous cell carcinoma (HNSCC), (chemo)radiation is the standard organ-sparing treatment; however, there is still a 50% (35–65%) recurrence rate [1]. In addition to clinical and histological parameters, other sophisticated biomarkers are needed to stratify patients for optimal therapy (e.g., de-escalation, escalation, or switching to surgery) [2, 3]. Being able to correctly identify patients with a favorable prognosis might allow treatment adaptation to reduce long-term toxicity without compromising outcome [4].

Functional imaging techniques capture a variety of biological characteristics, such as cellularity, perfusion, permeability, and glucose metabolism. Tissue microstructures (i.e., cellularity, necrosis, stroma, hemorrhage) can be assessed by diffusion-weighted MRI (DWI) and quantified by the apparent diffusion coefficient (ADC). An extension of DWI is the intravoxel incoherent motion (IVIM), which can assess both diffusion and perfusion fraction, without contrast injection [5–7].

Perfusion and vessel permeability can be assessed by dynamic contrast-enhanced (DCE) MRI and quantified by the $K_{\text{trans}}$ (transfer rate of contrast agent from plasma to extravascular, extracellular space), $V_e$ (fractional volume of extravascular extravascular space), and $K_{\text{ep}}$ (contrast agent transfer rate from extravascular, extracellular space to plasma) [8].

Glucose metabolism can be assessed by 18F-fluoro-deoxyglucose ($^{18}$F-FDG) positron emission tomography (PET) and is quantified by standardized uptake values (SUV) [9].

Combining modalities might improve predictive accuracy by capturing a variety of tumor characteristics in order to improve predictive accuracy. This could have clinical implications such as guidance for treatment planning, early treatment response, and outcome prediction [7, 10–15]. In contrast, overlapping parameters might be redundant and might reduce protocol efficiency [16]. The predictive values of DWI- and IVIM-MRI, DCE-MRI, and $^{18}$F-FDG-PET parameters of primary tumor (PT) and lymph node metastasis (LNM) have been only sporadically described in studies, without the use of multivariable Cox regression analysis [14, 17–20] or inclusion of clinical parameters (e.g., HPV status) [15, 21–24].

The aim of our study was to assess (I) the correlations between diffusion-weighted (DWI), intravoxel incoherent motion (IVIM), dynamic contrast-enhanced (DCE) MRI, and $^{18}$F-FDG-PET/CT imaging parameters capturing tumor characteristics and (II) their predictive value of locoregional recurrence-free survival (LRFS) and overall survival (OS) in patients with head and neck squamous cell carcinoma (HNSCC) treated with (chemo)radiotherapy.

**Materials and methods**

**Patient selection**

For this prospective single-center study, approved by our ethical committee (Trial NL3946, NTR4111), written informed consent was obtained from all patients. Previously untreated patients with histologically proven HNSCC, planned for
curative (chemo) radiotherapy, and those who underwent $^{18}$F-FDG-PET/low-dose CT and DWI-DCE-MRI were consecutively included between 2013 and 2018. Exclusion criteria were nasopharyngeal tumors, age $< 18$ and inadequate image quality. Within 5 weeks after baseline imaging, treatment was initiated consisting of pre-determined radiotherapy (70 Gy in 35 fractions in 7 weeks, or accelerated with 70 Gy in 35 fractions in 6 weeks) with/without concomitant chemotherapy (3-weekly 100 mg/m$^2$ cisplatin), or cetuximab (400 mg/m$^2$ before radiotherapy initiation and then weekly 250 mg/m$^2$ for 7 weeks). HPV status was determined by p16-immunostaining followed by DNA-PCR on p16-immuno-positive cases. In clinical practice, for lesions outside the oropharynx, HPV positivity is not causally associated with HNSCC [25] and not routinely tested for HPV status, therefore excluded in the survival analyses. Qualitative variables were transformed into numbers: gender (female = 0, male = 1), T-stage (T2 = 2, T3 = 3, T4 = 4), N-stage (N0 = 0, N1 = 1, N2 = 2), HPV (negative = 0, positive = 1), location PT (oropharynx = 1, hypopharynx = 2), smoking (pack years), alcohol (< 3 units/day = 0, ≥ 3 units/day = 1), intoxications (none = 0, smoking < 10 pack years = 0, alcohol < 3 units/day = 0, smoking > 10 pack years) or alcohol (> 3 units/day) = 1, smoking and alcohol use = 2) [26].

### Imaging

MRI was performed on a 3.0T Ingenity MR scanner (Philips Healthcare) utilizing a 16-channel neurovascular coil. DWI was performed using fat-suppressed single-shot spin-echo echo-planar imaging (SS-SE-EPI); TR = 500 ms, TE = 105 ms; echo-planar imaging factor = 35; sensitivity encoding factor = 3.5; field of view = $230 \times 230$ mm; slice thickness = 2 mm; intersection gap = 0.3 mm; matrix = $128 \times 128$; receiver bandwidth = 2735.7 Hz per pixel. Ten $2 \times 2$ mm; intersection gap = 0.3 mm; matrix = $128 \times 128$; receive-er factor = 3.5; field of view = $230 \times 230$ mm; slice thickness = 105 ms; echo-planar imaging factor = 35; sensitivity encoding echo-planar imaging (SS-SE-EPI); TR = 500 ms, TE = 144; 75 dynamic acquisitions of 4.16 s; signal averages = 144 × 144, and voxel size = $4 \times 4 \times 4$ mm. Post-reconstruction resolution was 5 mm full width at half maximum.

### Delineation

Whole-lesion delineation was performed manually by two independent observers (J.C. and P.dG., 30 and 15 years of experience in head and neck radiology, respectively) on the ADC map and DCE map. Herewith, T1w, STIR, and T2w maps were used for anatomical correlation, with knowledge of TNM stage and tumor location, but blinded for treatment outcome. Furthermore, the patient largest lymph node metastasis was delineated. DWI/IVIM delineation was performed with VELOCITY software (Varian). To assess the interobserver variability, the correlation (Pearson’s $r$), difference (Wilcoxon signed rank rest), and overlap of delineation (Dice index) were calculated.

$^{18}$F-FDG-PET/CT delineation was performed by semi-automatic delineation by a nuclear medicine specialist (B.Z.) using 50% of tumor-specific SUVpeak threshold, corrected for blood glucose level. Details on this method were published previously [29].

### Feature extraction

Imaging parameters were extracted from both PT and LNM whole-lesion ROIs of each observer. Anatomical total lesion volume, i.e., gross tumor volume (GTV), was calculated for each ROI on each imaging map ($\text{ADC}_{\text{GTV}}, \text{DCE}_{\text{GTV}},$ and metabolic active tumor volume (MATV)). The following quantitative imaging features were calculated per observer by averaging all voxels included in the whole-lesion ROI.

IVIM feature extraction of perfusion fraction ($f$), perfusion coefficient ($D^*$), and diffusion coefficient ($D$) was performed with Olea Sphere (Olea Medical, La Ciotat, France), after motion correction.

DCE-MRI analysis was processed with in-house built software (Dynamo; [27]), performing quantitative pharmacokinetic analysis using the 2-compartment Tofts model [8] with patient-specific arterial input function (AIF) obtained from manual delineating the most cranial part of the external carotid artery. The following features were extracted: $K^\text{trans}$ (transfer rate of contrast agent from plasma to extravascular, extracellular space); $V_e$ (fractional volume of extravascular extracellular space); $K_{\text{ep}}$ (transfer rate of contrast agent from extravascular, extracellular space to plasma).
Between 2013 and 2018, 81 patients were consecutively recruited (Fig. 1). Nine patients were excluded because of non-curative or surgical treatment and 2 because of significant low image quality.

The final study population consisted of 70 patients (Table 1) with a PT located in the oropharynx (n = 56) or hypopharynx (n = 14). Among the oropharyngeal tumors, the HPV status of 24 patients was positive (43%). Fifty-four patients received concurrent cisplatin-based chemoradiotherapy. Ten patients received weekly cetuximab with concurrent radiotherapy (70 Gy). Six patients received radiotherapy only.

The mean follow-up was 22.1 months (IQR 14.3–29.4). Seventeen patients (24.3%) developed locoregional recurrence. Twenty (28.6%) patients died during follow-up, all deaths being related to HNSCC (Table 1).

Associations of imaging parameters per subgroup

Seventy PT ROIs were drawn and 59 lymph node metastasis ROIs (largest LNM) on each modality (Table 1). The comparison of both observers resulted in no significant different values and a high interobserver correlation (Supplement 1). A Dice index in primary tumors of 0.88 at the DWI/IVIM and 0.85 at DCE delineation was found (not tabulated). For LNM, a Dice index of 0.97 at DCE and 0.92 at DWI/IVIM delineation was found (not tabulated). Primary tumor ADC$_{GTV}$, D, f, and D*, DCE$_{GTV}$, and all $^{18}$F-FDG-PET values (Supplement 2) were significantly higher in advanced T-staged tumors (all $p \leq 0.02$). In advanced N-staged tumors, PT ADC$_{GTV}$ and $V_e$ were significantly higher ($p = 0.021$ and $p = 0.023$, respectively). In HPV-negative tumors, ADC$_{mean}$, D, D*, SUV$_{max}$, SUV$_{mean}$, and SUV$_{peak}$ were significantly higher than HPV-positives ($p < 0.043$). In patients with intoxications, ADC$_{mean}$, D, and D* were significantly different among the different categories (all $p < 0.027$).

In LNM (Supplement 3), K ep and all $^{18}$F-FDG-PET parameters were significantly higher in advanced N-stages ($p = 0.025$, $p \leq 0.016$, respectively). In HPV-negative tumors, D was found to be significantly higher ($p = 0.002$) and D* lower ($p = 0.007$) than in HPV-positive tumors. In patients with intoxications, f was found to be significantly lower ($p = 0.026$).

Inter-modality correlations

The inter-modality correlation in PT between $^{18}$F-FDG-PET-, DWI/IVIM-, and DCE-derived parameters (Supplement 4) was only significant among GTV parameters (ADC$_{GTV}$, DCE$_{GTV}$, TLG, and MATV), SUV$_{peak}$, and SUV$_{mean}$ (range: $r = 0.434–0.915$). In LNM (Supplement 5), only volume parameters of LNM ADC$_{GTV}$, MATV, and DCE$_{GTV}$ correlated significantly (range: $r = 0.399–0.725$). The intra-modality correlation for PT and LNM (Supplement 6) resulted in significant internal moderate correlation of ADC parameters.
Locoregional recurrence-free survival

The univariate analysis (Table 2) showed that HPV-negative status and the combined intoxications were associated with locoregional recurrence (LRF; \( p = 0.036 \), \( p = 0.031 \), respectively). High ADC\(_{\text{GTV}}\), DCE\(_{\text{GTV}}\), \( K^{\text{trans}} \), \( V_e \), and MATV remained predictive for LRF (all \( p \leq 0.047 \)).

The multivariate analysis per modality (Table 2), corrected for significant clinical parameters (i.e., HPV and intoxications), showed that high primary tumor ADC\(_{\text{GTV}}\), DCE\(_{\text{GTV}}\), \( K^{\text{trans}} \), \( V_e \), and MATV remained predictive for LRF (all \( p \leq 0.048 \)). For LNM, only DCE\(_{\text{GTV}}\) remained significantly predictive for LRF (\( p = 0.018 \)). The subgroup analysis in HPV-negative patients is shown in Supplement 7.

The multivariable CoxBoost analysis (Table 4), combining all modalities and clinical parameters, showed that HPV status, intoxications, ADC\(_{\text{GTV}}\), \( K^{\text{trans}} \), and \( V_e \) remained predictive for LRF (C-index of 0.546). The log-rank test (Fig. 2)
showed that these risk factors were significantly predictive ($p = 0.023$) for LRF (Fig. 2b), whereas risk stratification per T-stage (Fig. 2a) was not significantly predictive ($p = 0.92$).

**Overall survival**

Primary tumor univariate analysis (Table 3) showed that clinical parameters HPV status, PT location, intoxications ($p \leq 0.047$), and imaging parameters $\text{ADC}_{\text{GTV}}$, $\text{ADC}_{\text{mean}}$, $D^*$, $D$, $\text{DCE}_{\text{GTV}}$, $V_e$, $\text{MATV}$, and $\text{SUV}_{\text{max}}$, were significantly associated with OS (all $p \leq 0.047$). For LNM, $\text{SUV}_{\text{max}}$, $\text{SUV}_{\text{mean}}$, and $\text{SUV}_{\text{peak}}$ were associated with OS (all $p \leq 0.015$).

In multivariate analysis per single modality (Table 3), corrected for clinical parameters (i.e., HPV status, hypopharyngeal PT location, intoxications), $\text{ADC}_{\text{GTV}}$ ($p = 0.004$), $D^*$ ($p = 0.016$), $\text{DCE}_{\text{GTV}}$ ($p = 0.001$), $V_e$ ($p = 0.019$), $\text{MATV}$ ($p = 0.088$), and $\text{SUV}_{\text{max}}$ ($p = 0.001$) remained predictive for OS. In LNM, only $\text{SUV}_{\text{max}}$ ($p = 0.055$, HR = 0.563) and $\text{SUV}_{\text{mean}}$ ($p = 0.005$, HR = 3.536) remained predictive for OS. The subgroup analysis in HPV-negative patients is shown in Supplement 7.

The multivariable CoxBoost analysis combining all PT parameters of all modalities, including all clinical parameters (Table 4), shows that N-stage, HPV status, PT location, intoxications, PT $\text{ADC}_{\text{GTV}}$, $\text{ADC}_{\text{mean}}$, $D^*$, $K_{\text{trans}}$, $V_e$, $\text{SUV}_{\text{max}}$, and TLG remain predictive for OS, with a C-index of 0.664.

Predictive parameters scored as risk factors for OS (Fig. 2) were significantly predictive ($p = 0.046$) in the log-rank test (Fig. 2d) when combined, whereas risk stratification per T-stage (Fig. 2c) was found not significant ($p = 0.188$).

**Discussion**

In this study, correlations between pretreatment DWI/IVIM, DCE-MRI, and $^{18}$F-FDG-PET/CT parameters were assessed in order to capture predictive tumor characteristics for LRFS and OS in pharyngeal SCC patients treated with (chemo)radiotherapy.

**Tumor characteristics**

Advanced stage tumors (high T-stage) and HPV-negative status had significant higher diffusion (high $\text{ADC}_{\text{mean}}$, $D$), higher permeability ($K_{\text{trans}}$, $V_e$), and lower perfusion (low $\gamma$ and $D^*$), implying different tumor characteristics than early stage and
Table 2  Univariable and multivariable prediction analysis of locoregional recurrence-free survival

| n = 70 patient parameters | Local control | Recurrence | Univariable* | Multivariable** |
|---------------------------|---------------|------------|--------------|-----------------|
|                           | Mean ± SD     | Mean ± SD  | p value*     | p value         | HR (95% CI)     |
| **Mean ± SD**             | **Mean ± SD** | **p value**| **p value**  | **HR (95% CI)** |
| **Clinical parameters**   |               |            |              |                 |                 |
| Gender                    | 0.7 ± 0.5     | 0.6 ± 0.5  | 0.665        | –               | –               |
| Age                       | 62.6 ± 7.9    | 65.1 ± 6.2 | 0.167        | –               | –               |
| T-stage                   | 3.0 ± 0.9     | 3.1 ± 0.9  | 0.929        | –               | –               |
| N-stage                   | 1.4 ± 0.8     | 1.8 ± 0.4  | 0.695        | –               | –               |
| HPV                       | 0.4 ± 0.5     | 0.2 ± 0.4  | 0.036        | 0.036           | 0.26 (0.08–0.91) |
| Location PT               | 1.2 ± 0.4     | 1.2 ± 0.44 | 0.543        | –               | –               |
| Smoking (PY)              | 22.8 ± 18.7   | 30.1 ± 17.3| 0.101        | –               | –               |
| Alcohol (≥3 drinks/day)   | 0.43 ± 0.5    | 0.7 ± 0.5  | 0.054        | –               | –               |
| Intoxications             |               |            |              |                 |                 |
| None                      | 0.9 ± 0.8     | 1.4 ± 0.8  | 0.054        | –               | –               |
| Smoking or alcohol use    | –             | –          | 0.525        | –               | –               |
| Smoking and alcohol use   | –             | –          | 0.031        | –               | –               |
| **Primary tumors**        |               |            |              |                 |                 |
| DWI ADCGTV (cm³)          | 0.8 ± 0.7     | 1.2 ± 1.4  | 0.023        | 0.021           | 1.69 (1.08–2.64) |
| ADC (× 10⁻³ mm²/s)        | 1.2 ± 0.2     | 1.2 ± 0.2  | 0.166        | –               | –               |
| IVIM D* (× 10² mm²/s)     | 0.18 ± 0.1    | 0.18 ± 0.06| 0.535        | –               | –               |
| D (mm²/s)                 | 0.96 ± 0.2    | 1.0 ± 0.2  | 0.373        | –               | –               |
| F (× 10² mm²/s)           | 1.4 ± 0.5     | 1.3 ± 0.6  | 0.342        | –               | –               |
| DCE DCE GTV (cm³)         | 11.6 ± 7.8    | 16.1 ± 14.6| 0.047        | 0.016           | 1.06 (1.01–1.10) |
| Kep (min⁻¹)               | 1.1 ± 0.4     | 1.2 ± 0.6  | 0.138        | –               | –               |
| Ktrans (min⁻¹)            | 0.6 ± 0.3     | 0.74 ± 0.3 | 0.027        | 0.017           | 8.50 (1.68–43.1)|
| Ve                         | 1.2 ± 0.8     | 2.0 ± 1.6  | 0.008        | 0.015           | 1.64 (1.10–2.43)|
| ¹⁸F-FDG-PET MATV (cm³)    | 9.7 ± 7.6     | 13.7 ± 16.5| 0.066        | 0.048           | 1.04 (1.00–1.09) |
| SUV_max (Bq)              | 8.3 ± 3.9     | 8.7 ± 5.9  | 0.158        | –               | –               |
| SUV_mean (Bq)             | 6.0 ± 2.4     | 6.5 ± 3.8  | 0.193        | –               | –               |
| SUV_peak (Bq)             | 7.3 ± 3.2     | 8.1 ± 5.1  | 0.133        | –               | –               |
| TLG (Bq × cm³)            | 66.2 ± 70.3   | 93.2 ± 104.3| 0.039       | –               | –               |
| Lymph node metastases     |               |            |              |                 |                 |
| DWI ADCGTV (10³ cm³)      | 5.9 ± 4.9     | 6.1 ± 4.9  | 0.588        | –               | –               |
| ADC (× 10³ mm²/s)         | 1.1 ± 0.24    | 1.2 ± 0.3  | 0.596        | –               | –               |
| IVIM D* (mm²/s)           | 2.6 ± 0.7     | 2.6 ± 0.7  | 0.914        | –               | –               |
| D (mm²/s)                 | 0.78 ± 0.2    | 0.8 ± 0.2  | 0.485        | –               | –               |
| f (× 10² mm²/s)           | 1.8 ± 0.6     | 1.76 ± 0.7 | 0.892        | –               | –               |
| DCE DCE GTV (cm³)         | 4.7 ± 3.5     | 6.4 ± 4.7  | 0.076        | 0.018           | 1.18 (1.03–1.36) |
| Kep (min⁻¹)               | 0.9 ± 0.6     | 1.1 ± 0.7  | 0.692        | –               | –               |
| Ktrans (min⁻¹)            | 1.2 ± 1.1     | 1.4 ± 1.4  | 0.764        | –               | –               |
| Ve                         | 1.3 ± 0.9     | 1.4 ± 1.5  | 0.653        | –               | –               |
| ¹⁸F-FDG-PET MATV (cm³)    | 6.2 ± 7.3     | 6.4 ± 5.7  | 0.452        | –               | –               |
| SUV_max (Bq)              | 8.0 ± 4.4     | 8.4 ± 3.1  | 0.554        | –               | –               |
| SUV_mean (Bq)             | 5.0 ± 2.4     | 5.4 ± 1.9  | 0.407        | –               | –               |
| SUV_peak (Bq)             | 6.1 ± 3.3     | 6.6 ± 2.6  | 0.371        | –               | –               |
| TLG (Bq × cm³)            | 7.6 ± 12.4    | 7.9 ± 10.3 | 0.354        | –               | –               |

*Univariable Cox regression analysis
**Multivariable Cox regression analysis

Univariable and multivariate Cox regression analysis for locoregional recurrence of primary tumor and lymph node metastasis imaging parameters, compared between responders and non-responders. In the multivariate analysis, all parameters per modality were combined, which lead to a loss of intoxications and TLG as remaining predictive parameters for locoregional recurrence.
HPV-positive tumors. These parameters were also found to be associated with an adverse outcome. This is in line with literature, which described the decrease of cellularity due to apoptosis/necrosis (increased ADC_{mean} and D) to be associated with treatment resistance and thereby with poor prognosis [18]. In contrast, in studies which excluded areas of necrosis in the ROI, lower ADC values were found in high-grade tumors with high cellularity. In the current study, HPV-negative patients had a higher ADC value than HPV-positive patients, which was in line with other studies regardless of including [10] or excluding [32–35] necrotic areas. An increase of permeability (increased K_{trans}) is possibly due to tumor neoangiogenesis, which increases immature incompetent vessel leakage, thereby increasing the fraction in the extracellular extravascular space (increased V_e), causing higher interstitial fluid pressure and lower flow [16, 36]. The reduced perfusion (low blood flow and volume; low D^n and f, respectively) results in worse access to chemotherapeutic drugs and oxygen for radiosensitivity, and is associated with an adverse outcome. This reduced perfusion was found in larger, more advanced stage tumors, and is indicative for low microvessel density, low velocity and hypoxia, due to the incompetent microvessels and increased interstitial pressure [16, 18, 37, 38]. A high/or increased metabolism was also associated with adverse outcome, which might be due to a high/increased glucose demand of advanced staged tumors [39], due to proliferating malignant cells and stromal tissue. In contrast, reduced metabolism in the tumoral center due to diminished access of nutrition and oxygen supply, leading to necrosis with hypoxia, was also associated with adverse outcome [40]. These tumor characteristics might be used to target subvolumes for dose-paint RT [2, 3, 15].

**Recurrence-free survival**

In the present study, the combination of HPV status, tumor volume (ADC_{GTV}), high K_{trans}, and high V_e showed more predictive potential for locoregional control than the clinically used risk stratification per T-stage. The more of these adverse factors, the worse the locoregional-free survival was. The previously described predictive value of K_{trans} [21, 23] and V_e was confirmed in this study [22, 23]. In contrast, Ng et al [41]...
Table 3  Univariable and multivariable prediction analysis for overall survival

| n = 70 patient parameters | Survival | Death | Univariable* | Multivariable** |
|--------------------------|----------|-------|--------------|-----------------|
|                          | Median   | Median | p value      | p value         |
|                          |          |        |              | HR (95%CI)      |
| **Clinical parameters**  |          |        |              |                 |
| Gender                   | 0.6 ± 0.5| 0.8 ± 0.4 | 0.321        | –               |
| Age                      | 62.4 ± 8.0| 65.2 ± 6.0 | 0.129        | –               |
| T-stage                  | 3 ± 0.9 | 3.3 ± 0.9 | 0.208        | –               |
| N-stage                  | 1.4 ± 0.8| 1.7 ± 0.7 | 0.214        | –               |
| HPV                      | 0.5 ± 0.5| 0.1 ± 0.3 | 0.008        | 0.008           |
| Location PT              | 1.1 ± 0.3| 1.4 ± 0.5 | 0.047        | –               |
| Smoking (PY)             | 22.3 ± 18.9| 30.1 ± 16.8 | 0.066        | –               |
| Alcohol (≥3drinks/day)   | 0.4 ± 0.5| 7 ± 0.5 | 0.09         | –               |
| Intoxications            | 0.9 ± 0.8| 1.5 ± 0.8 | 0.029        | –               |
| None                     | –        | –       | 0.255        | –               |
| Smoking or alcohol use   | –        | –       | 0.012        | –               |
| Smoking and alcohol use  | –        | –       | –            | –               |
| **Primary tumors**       |          |        |              |                 |
| DWI                      | ADCGTV (× 10^3 cm^3) | 0.7 ± 0.7 | 1.35 ± 1.3 | 0.004 | 0.004 | 1.748 (1.20–2.55) |
|                         | ADCmean (× 10^3 mm^2/s) | 1.2 ± 0.2 | 1.3 ± 0.2 | 0.024 | –       |
| IVIM                     | D^* (× 10^3 mm^2/s) | 0.19 ± 0.07 | 0.16 ± 0.05 | 0.032 | 0.016 | <0.001 (0.001–0.1) |
|                         | D (mm^2/s) | 0.9 ± 0.2 | 1.0 ± 0.2 | 0.009 | –       |
|                         | f (× 10^3 mm^2/s) | 1.4 ± 0.5 | 1.5 ± 0.5 | 0.786 | –       |
| DCE                     | DCEGTV (cm^3) | 10.7 ± 10.7 | 17.5 ± 13.7 | 0.006 | 0.001 | 1.059 (1.02–1.11) |
|                         | Ktrans (min^-1) | 1.1 ± 0.4 | 1.2 ± 0.5 | 0.219 | –       |
|                         | Ktrans (min^-1) | 0.59 ± 0.3 | 0.68 ± 0.3 | 0.089 | –       |
|                         | Vc | 1.2 ± 0.7 | 2.0 ± 1.7 | 0.004 | 0.019 | 5.514 (1.32–23.1) |
| ^18F-FDG-PET            | MATV (cm^3) | 8.9 ± 6.7 | 15.0 ± 15.9 | 0.003 | 0.088 | 1.039 (0.99–1.09) |
|                         | SUVmax (Bq) | 8.6 ± 3.4 | 11.6 ± 5.8 | 0.001 | 0.001 | 1.189 (1.07–1.32) |
|                         | SUVmean (Bq) | 5.6 ± 2.1 | 7.4 ± 3.8 | 0.001 | –       |
|                         | SUVpeak (Bq) | 6.8 ± 2.7 | 9.2 ± 5.0 | 0.001 | –       |
|                         | TLG (Bq cm^3) | 55.7 ± 56.1 | 114 ± 111 | 0.0002 | –       |
| **Lymph node metastasis** |          |        |              |                 |
| DWI                      | ADCGTVV (× 10^3) | 6.0 ± 4.5 | 5.9 ± 5.2 | 0.91 | –       |
|                         | ADCmean | 1.1 ± 0.06 | 1.1 ± 0.3 | 0.757 | –       |
| IVIM                     | D^* (× 10 mm^2/s) | 2.6 ± 0.7 | 2.6 ± 0.8 | 0.915 | –       |
|                         | D (mm^2/s) | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.233 | –       |
|                         | f (× 10^2 mm^2/s) | 1.8 ± 0.5 | 1.8 ± 0.6 | 0.44 | –       |
| DCE                     | DCEGTV (cm^3) | 5.1 ± 3.9 | 5.0 ± 4.0 | 0.905 | –       |
|                         | Ktrans (min^-1) | 1.0 ± 0.6 | 0.9 ± 0.5 | 0.607 | –       |
|                         | Ktrans (min^-1) | 1.2 ± 0.9 | 1.5 ± 1.6 | 0.388 | –       |
|                         | Vc | 1.2 ± 0.7 | 1.6 ± 1.4 | 0.131 | –       |
| ^18F-FDG-PET            | MATV (cm^3) | 5.8 ± 5.7 | 7.3 ± 9.1 | 0.177 | –       |
|                         | SUVmax (Bq) | 7.3 ± 3.7 | 10.0 ± 4.3 | 0.015 | 0.055 | 0.563 (0.43–0.74) |
|                         | SUVmean (Bq) | 4.6 ± 2.1 | 6.3 ± 2.3 | 0.005 | 0.022 | 3.536 (2.56–5.26) |
|                         | SUVpeak (Bq) | 5.6 ± 2.8 | 7.7 ± 4.5 | 0.009 | –       |
|                         | TLG (Bq cm^3) | 7.0 ± 10.0 | 9.1 ± 15.6 | 0.143 | –       |

* Univariate Cox regression analysis
** Multivariable Cox regression per modality

Univariable and multivariable Cox regression analysis of PT and LNM between survivors and patients who died. In the multivariable analysis, all parameters per modality were combined, which lead to a loss of hypopharyngeal PT location, intoxications, ADCmean, D, Ktrans, SUVmean, SUVpeak and TLG, and LNM SUVpeak as remaining predictive parameters for OS.
The combination of all modalities showed that N-stage, HPV-negative status, hypopharyngeal PT location, and intoxication were risk factors for adverse overall survival. This was in line with other studies who found hypopharyngeal PT location [44], alcohol use [23], and HPV status [24] as predictors.

Besides, a large tumor volume (ADC GTV, DCE GTV, MATV), K trans, and V e (as were predictive for adverse LRFS), also high ADC mean, D*, SUV max, and TLG, were predictive for adverse OS. The more of these adverse factors, the worse the overall survival was. Previous studies performing multivariable analysis were in line with these findings and found that V e [22] and K trans were predictive for OS. The pretreatment finding of low ADC mean was associated with highly cellular tumors including rapidly dividing cells, which are more sensitive to subsequent chemotherapy and radiotherapy and

---

### Table 4 Multimodality CoxBoost regression analysis

| Parameters       | Locoregional recurrence-free survival (LRFS) (C-index = 0.546) | Overall survival (OS) (C-index = 0.664) |
|------------------|---------------------------------------------------------------|----------------------------------------|
|                  | Hazard ratio | 95% CI** | Hazard ratio | 95% CI** |
| Clinical         | Gender        | –         | –            | –         |
|                  | Age           | –         | –            | –         |
|                  | T-stage       | –         | –            | –         |
|                  | N-stage       | –         | 1.058 | 0.66–5.14 |
|                  | HPV-positive status* | 0.889 | 0.08–1.16 | 0.886 | 0.07–2.50 |
|                  | Location (hypopharynx) | –         | 1.111 | 1.07–9.70 |
|                  | Smoking (> 10 PY) | –         | –            | –         |
|                  | Intoxications (none/smoke-or-alc/both) | 1.065 | 0.83–3.89 | 1.145 | 0.93–5.22 |
| DWI              | ADC GTV       | 1.293 | 1.00–2.56 | 1.102 | 0.54–4.23 |
|                  | ADC mean      | –         | 1.137 | 0.07–42.02 |
| IVIM             | D*            | –         | 0.862 | 0.00–56.27 |
|                  | D             | –         | –            | –         |
|                  | f             | –         | –            | –         |
| DCE              | DCE GTV       | –         | –            | –         |
|                  | K ep          | –         | –            | –         |
|                  | K trans       | 1.223 | 1.09–28.01 | 1.106 | 0.79–29.10 |
|                  | V e           | 1.214 | 0.90–1.92 | 1.195 | 0.76–1.68 |
| 18F-FDG-PET/CT   | MATV          | –         | –            | –         |
|                  | SUV max       | –         | 1.094 | 0.93–1.27 |
|                  | SUV mean      | –         | –            | –         |
|                  | SUV peak      | –         | –            | –         |
|                  | TLG           | –         | 1.433 | 0.99–1.02 |

*HPV-negative status: HR = 1.1074 for recurrence, HR = 1.1284
**The 95% confidence intervals were calculated from the multivariable analysis

Multivariable CoxBoost regression analysis of primary tumor imaging parameters to predict locoregional recurrence and overall survival. The C-index (taking the area under the curve over time into account) and hazard ratios (HR) are shown. The adverse locoregional recurrence-free survival is predicted significantly by HPV negativity, intoxications, ADC GTV, K trans, and V e. The adverse overall survival predicted significantly by N-stage, HPV negativity, hypopharyngeal tumor location, intoxications, ADC GTV, ADC mean, D*, K trans, V e, SUV max, and TLG.

---

Overall survival

The combination of all modalities showed that N-stage, HPV-negative status, hypopharyngeal PT location, and intoxication were risk factors for adverse overall survival. This was in line with other studies who found hypopharyngeal PT location [44], alcohol use [23], and HPV status [24] as predictors.

Besides, a large tumor volume (ADC GTV, DCE GTV, MATV), K trans, and V e (as were predictive for adverse LRFS), also high ADC mean, D*, SUV max, and TLG, were predictive for adverse OS. The more of these adverse factors, the worse the overall survival was. Previous studies performing multivariable analysis were in line with these findings and found that V e [22] and K trans were predictive for OS. The pretreatment finding of low ADC mean was associated with highly cellular tumors including rapidly dividing cells, which are more sensitive to subsequent chemotherapy and radiotherapy and
therefore associated with a more favorable prognosis [18, 19]. A possible explanation for the extra predictors for OS compared with the predictors of LRFS is that certain tumor tissue architecture, e.g., heterogeneous tissue with low diffusion restriction (high ADC\textsubscript{mean}) and aggressive high metabolism (high SUV\textsubscript{max} and TLG), is less sensitive to (chemo)radiotherapy, which additionally decreases tumor control and survival.

In previous studies, smoking, K\textsubscript{trans}, K\textsubscript{ep} [23, 41], and a heterogeneous 18\textsuperscript{F}-FDG-PET/CT parameter (18\textsuperscript{F}-FDG-PET uniformity) were reported to be predictive for OS. In contrast, the significant predictive value of the various clinical parameters combined with significant parameters from the whole spectrum of DWI with IVIM, DCE, and 18\textsuperscript{F}-FDG-PET/CT was not described previously. The aforementioned risk factors for adverse OS were found significantly predictive, whereas stratification per T-stage was not significantly predictive. This implies an additional predictive value of functional imaging to clinical staging based on morphology.

**Complementarity and applicability**

In order to improve prediction accuracy, the complementary value of each imaging modality is of importance to capture the whole spectrum of predictive tumoral characteristics, such as tumoral cellularity, necrosis, vascularity, and metabolism [11–13, 16, 24]. Previously described hypothetical overlapping parameters, such as DWI, IVIM (e.g., ADC\textsubscript{mean} and D), both capturing tissue cellularity indirectly, and DCE (e.g., K\textsubscript{trans} with K\textsubscript{ep}) [11, 12, 45], correlated not evidently in this study. Different heterogeneous tumor architecture (inflammation, fibrosis, necrosis, and hypoxia) and/or HPV status in more advanced staged tumors might have caused the loss of correlations. Further optimization of protocols and selection and evaluation of qualitative and quantitative parameters is necessary in future studies.

The current study underlines the superiority of combining MRI and 18\textsuperscript{F}-FDG-PET/CT, which allowed combining significant predictive clinical parameters, such as HPV-negative status, intoxication (smoking/alcohol), hypopharyngeal tumor location, and N-stage with predictive quantitative imaging parameters: ADC\textsubscript{mean} (DWI) and D\textsuperscript{*} (IVIM), K\textsubscript{trans}, V\textsubscript{e} (DCE) and SUV\textsubscript{max}, and TLG (18\textsuperscript{F}-FDG-PET/CT) for OS. In this way, risk stratification on a patient level was shown to be possible. Furthermore, this might improve patient care and pave the road for personalized treatment options by identification and targeting tumoral subvolumes which are predictive for adverse outcome [7, 46].

**Limitations**

There was a relatively low incidence of events in our cohort; therefore, this study should be considered as hypothesis-generating. Also, selection bias might have occurred by excluding surgical treatment at the prospective selection of patients with curative (chemo)radiotherapy.

Secondly, although T-stage is dependent on the gross tumor volume, they were both included in the predictive analysis, which might have caused confounding bias. Although in this study the GTV was determined on functional imaging maps (ADC and DCE maps), it should be evaluated in future studies whether GTV determined on anatomical MRI sequences is more accurate in the predictive analyses.

Thirdly, we performed pharmacokinetic modeling analysis by using a patient-specific AIF, measured in the external carotid arteries. Flow artifacts as well as high concentrations of contrast agent can result in incorrect amplitude of the arterial concentration. This can affect final calculation of K\textsubscript{trans} and V\textsubscript{e} which, as a consequence, are over-estimated (e.g., V\textsubscript{e} can be larger than 1). We have decided to leave the results as we obtained them, but in future studies, we intend to correct the AIF for flow artifacts.

Finally, the LNM parameters were based on the ROIs of the largest lymph node metastasis, which might falsely ignore the adverse effect of having multiple metastases and consisting of necrotic tumoral areas, which reduced the average tumoral FDG uptake. The LNM parameters were excluded in the multimodality CoxBoost analysis in order to remain statistically robust, which might have limited the predictive value. Moreover, only internal validation by bootstrap cross-validation was feasible. These limitations were managed by performing a well setup internal validation by bootstrap cross-validation to test limited parameters repeatedly in a subset.

**Conclusion**

The combination of clinical parameters, HPV status, with DCE, IVIM-MRI, and 18\textsuperscript{F}-FDG-PET/CT, provided complementary value in capturing tumor characteristics and improved prediction of locoregional recurrence-free survival and overall survival. HPV-negative status, intoxications, high tumor volume, and permeability and extravascular extracellular space on DCE imaging were predictive for locoregional recurrence and decreased overall survival. Additionally, low cellularity on the ADC map and high metabolism on the 18\textsuperscript{F}-FDG-PET/CT were additionally predictive for adverse overall survival.

**Funding information** This research was funded by the Netherlands Organisation for Health Research and Development, grant 10-10400-98-14002. The funding source had no involvement in collection, analysis, data interpretation, writing of the report, nor in the decision to submit the article for publication.

**Compliance with ethical standards**

Guarantor The scientific guarantor of this publication is Prof. Dr. Jonas Castelijns, MD, PhD.
Conflict of interest  The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Statistics and biometry  One of the authors has significant statistical expertise.
Carel F.W. Peeters, PhD.
Department of Epidemiology and Biostatistics, Amsterdam UMC, De Boelelaan 1117, Amsterdam, the Netherlands.

Informed consent  Written informed consent was obtained from all subjects (patients) in this study.

Ethical approval  Institutional Review Board approval was obtained.

Methodology
• retrospective
• prognostic study
• performed at one institution

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Brockstein B, Haraf DJ, Rademaker AW et al (2004) Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 15(8):1179–1186
2. Schuller DE, Grecula JC, Agrawal A et al (2002) Multimodal intensification therapy for previously untreated advanced resectable squamous cell carcinoma of the oral cavity, oropharynx, or hypopharynx. Cancer. 94(12):3169–3178
3. Mirghani H, Blanchard P (2018) Treatment de-escalation for HPV-driven oropharyngeal cancer: where do we stand? Clin Transl Radiat Oncol 8:4–11
4. Machaty M, Jennifer M, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26(21):3582–3589
5. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laljeantet M (1988) Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology. 168:497–505
6. Noij DP, Martens RM, Marcus JT et al (2017) Intravoxel incoherent motion magnetic resonance imaging in head and neck cancer: a systematic review of the diagnostic and prognostic value. Oral Oncol 68:81–91
7. Payabvash S (2018) Quantitative diffusion magnetic resonance imaging in head and neck tumors. Quant Imaging Med Surg 8(10): 1052–1065
8. Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 10(3):223–232
9. Kwon SH, Yoon JK, An YS et al (2014) Prognostic significance of the intratumoral heterogeneity of (18) F-FDG uptake in oral cavity cancer. J Surg Oncol 110(6):702–706
10. de Perrot T, Lenoir V, Domingo Ayllon M, Dulguerov N, Pusztafzeri M, Becker M (2017) Apparent diffusion coefficient histograms of human papillomavirus-positive and human papillomavirus-negative head and neck squamous cell carcinoma: assessment of tumor heterogeneity and comparison with histopathology. AJNR Am J Neuroradiol 38(11):2153–2160
11. Han M, Kim SY, Lee SJ, Choi JW (2015) The correlations between MRI perfusion, diffusion parameters, and 18F-FDG PET metabolic parameters in primary head-and-neck cancer: a cross-sectional analysis in single institute. Medicine. 94(47):e2141. https://doi.org/10.1097/MD.0000000000002141
12. Marzi S, Pluhu F, Forina C et al (2017) Correlation study between intravoxel incoherent motion MRI and dynamic contrast-enhanced MRI in head and neck squamous cell carcinoma: evaluation in primary tumors and metastatic nodes. Magn Reson Imaging 37:1–8
13. Xu XQ, Choi YJ, Sung YS et al (2016) Intravoxel incoherent motion MR imaging in the head and neck: correlation with dynamic contrast-enhanced MRI imaging and diffusion-weighted imaging. Korean J Radiol 17(5):641–649
14. Bonomo P, Merlotti A, Olmetto E et al (2018) What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemotherapy? A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 45(12):2122–2138
15. Rumley CN, Lee MT, Holloway L et al (2017) Multiparametric magnetic resonance imaging in mucosal primary head and neck cancer: a prospective imaging biomarker study. BMC Cancer 17(1):475
16. Leifels L, Purz S, Stumpp P et al (2017) Associations between (18)F-FDG-PIPET, DWI, and DCE parameters in patients with head and neck squamous cell carcinoma depend on tumor grading. Contrast Media Mol Imaging 2017:1–8
17. Chawla S, Kim S, Loever LA et al (2011) Prediction of disease-free survival in patients with squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. AJNR AJNR Am J Neuroradiol 32(4):778–784
18. Chawla S, Kim S, Dougherty L et al (2013) Pretreatment diffusion-weighted and dynamic contrast-enhanced MRI prediction of local treatment response in squamous cell carcinomas of the head and neck. AJR Am J Roentgenol 200(1):35–43
19. King AD, Mo FK, Yu KH et al (2010) Squamous cell carcinoma of the head and neck: diffusion-weighted MRI imaging for prediction and monitoring of treatment response. Eur Radiol 20(9):2213–2220
20. Kim S, Loever LA, Quon H et al (2010) Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MRI imaging. AJNR AJNR Am J Neuroradiol 31(2):262–268
21. Ng SH, Lin CY, Chan SC et al (2013) Dynamic contrast-enhanced MR imaging predicts local control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. PLoS One 8(8):e72230. https://doi.org/10.1371/journal.pone.0072230
22. Ng SH, Lin CY, Chan SC et al (2014) Clinical utility of multimodality imaging with dynamic contrast-enhanced MRI, diffusion-weighted MRI, and 18F-FDG PET/CT for the prediction of neck control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. PLoS One 9(12):e115933. https://doi.org/10.1371/journal.pone.0115933

Eur Radiol (2021) 31:616–628
627
23. Chan SC, Cheng NM, Hsieh CA et al (2017) Multiparametric imaging using 18 parameters and functional MRI-F-FDG PET/CT heterogeneity techniques: association with head and neck cancer. J Radiol 98(7-8):626-6262

24. Schouten CS, Haikin S, Boellaard R et al (2016) Interaction of quantitative (18)F-FDG-PET-CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma. Head Neck 38(4):529-535

25. Vokes EE, Agrawal N, Seiwert TY (2017) HPV-associated head and neck cancer. J Natl Cancer Inst 109(12):344

26. Hashibe M, Brennan P, Benhamou S et al (2007) Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 99(10):777-789

27. Lavini C, Kramer G, Pieters-den Bos I, Hoekstra O, Marcus JT (2017) MRI protocol optimization for quantitative DCE-MRI of the spine. Magn Reson Imaging 44:96-103

28. Boellaard R, Delgado-Bolton R, Oyen WJG et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42(2):328-354

29. Frings V, Van Velden FHP, Velasquez LM et al (2014) Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study. Radiology. 273(2):538-548

30. Moons KG, Altman DG, Reitsma JB (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 162(1):W1-W73

31. Collins GS, Reitsma JB, Altman DG, Moons KG (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 162(1):55-63

32. Schouten CS, de Graaf P, Bloemena E et al (2015) Quantitative diffusion-weighted MRI parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma. AJNR Am J Neuroradiol 36(4):763-767

33. Chan MW, Higgins K, Enepekides D et al (2016) Radiologic differences between human papillomavirus-related and human papillomavirus-unrelated oropharyngeal carcinoma on diffusion-weighted imaging. Oral Oncol. 78(6):344-352

34. Wong KH, Panek R, Welsh L et al (2016) The predictive value of early assessment after 1 cycle of induction chemotherapy with 18F-FDG PET/CT and diffusion-weighted MRI for response to radical chemoradiotherapy in head and neck squamous cell carcinoma. J Nucl Med 57(12):1843-1850

35. Driessen JP, van Bemmel AJ, van Kempen PM et al (2015) Correlation of human papillomavirus status with apparent diffusion coefficient of diffusion-weighted MRI in head and neck squamous cell carcinomas. Head Neck 38:616-626E8

36. Nakajo M, Nakajo M, Kajiya Y et al (2012) FDG PET/CT and diffusion-weighted imaging of head and neck squamous cell carcinoma: comparison of prognostic significance between primary tumor standardized uptake value and apparent diffusion coefficient. Clin Nucl Med 37(5):475-480

37. Agrawal S, Awasthi R, Singh A, Haris M, Gupta RK, Rathore RKS (2012) An exploratory study into the role of dynamic contrast-enhanced (DCE) MRI metrics as predictors of response in head and neck cancers. Clin Radiol 67(9):1-5

38. Guo W, Luo D, Lin M et al (2016) Pretreatment intra-voxel incoherent motion diffusion-weighted imaging (IVIM-DWI) in predicting induction chemotherapy response in locally advanced hypopharyngeal carcinoma. Medicine. 95(10):e3039. https://doi.org/10.1097/MD.0000000000003039

39. Covello M, Cavalliere C, Aiello M et al (2015) Simultaneous PET/CT head-neck cancer imaging: preliminary clinical experience and multiparametric evaluation. Eur J Radiol 84(7):1269-1276

40. Han MW, Lee HJ, Cho KJ et al (2012) Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck 34(10):1395-1402

41. Ng SH, Liao CT, Lin CY et al (2016) Dynamic contrast-enhanced MRI, diffusion-weighted MRI and (18)F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. Eur Radiol 26(11):4162-4172

42. Hatakenaka M, Nakamukida K, Yabuuchi H et al (2011) Pretreatment apparent diffusion coefficient of the primary lesion correlates with local failure in head-and-neck cancer treated with chemoradiotherapy or radiotherapy. Int J Radiat Oncol Biol Phys 81(2):339-345

43. Kim S, Loevner L, Quon H et al (2009) Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 15(3):986-994

44. Lehnerdt GF, Franz P, Zaqoul P et al (2008) Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene. Clin Cancer Res 14(6):1753-1758

45. Surov A, Stumpf P, Meyer HJ et al (2016) Simultaneous (18)F-FDG-PET/MRI: associations between diffusion, glucose metabolism and histopathological parameters in patients with head and neck squamous cell carcinoma. Oral Oncol 58:14-20

46. Chow LQM (2020) Head and neck cancer. N Engl J Med 382(1):60-72

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.